<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="383">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01507506</url>
  </required_header>
  <id_info>
    <org_study_id>08 TETE 01</org_study_id>
    <nct_id>NCT01507506</nct_id>
  </id_info>
  <brief_title>Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma</brief_title>
  <acronym>SPECTRO GLIO</acronym>
  <official_title>Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-institutional phase III clinical  study of interventional type. The trial
      will include 220 patients with confirmed unifocal glioblastoma over a period of 3 years + 3
      years of follow up.

      Patients with unifocal glioblastoma (diagnosis confirmed by histology on tumoral biopsy or
      surgical specimen) and who meet all eligibility criteria will be randomized in one
      chemoradiotherapy arm :

        -  Conventional arm: 3-dimensional conformational radiotherapy + Temozolomide

        -  Experimental arm : simultaneous-integrated boost with intensity-modulated radiotherapy
           guided by magnetic resonance spectroscopic imaging + Temozolomide The patient
           monitoring will be regular and standardized. The main objective of this study is to
           improve overall survival of patients treated in experimental group (with simultaneous
           integrated boost).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival defined as the time from randomization to the date of death or date of last follow-up news (censured data)</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, defined as the time from randomization to the date of progression or death</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluated according to the classification of NCI CTCAE (Common Terminology Criteria for Adverse Events)V3.0</measure>
    <time_frame>8 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Conventional arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-dimensional conformal radiotherapy + Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.
+
Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,
post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.</description>
    <arm_group_label>Conventional arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Experimental arm</intervention_name>
    <description>Conformational radiotherapy with simultaneous integrated boost  by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA&gt; 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed
+
Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,
post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have unifocal glioblastoma (grade IV astrocytoma, WHO classification).
             The GBM can be:

               -  Or resectable and the patient has received curative surgery

               -  Or unresectable, and the largest tumor diameter (contrast enhancement) must be
                  less than 5 cm on MRI

          2. In all cases, the diagnosis must be confirmed by a pathologist. In patients for whom
             surgery is not possible, the diagnosis is confirmed by a biopsy of tumor tissue.

          3. Methylation status of MGMT gene promoter is known

          4. Patients who have undergone resection should have received an MRI or a scan after
             surgery in order to visualize residual tumor. If not, the operative report must be
             available.

          5. Surgery or biopsy must have occurred 45 days before the start of radiotherapy.

          6. WHO ≤ 2

          7. Age ≥ 18 years

          8. Signed Consent collected before any specific procedure in the study

          9. Patient member in a national insurance scheme

        Exclusion Criteria:

          1. Signs of hemorrhage on pre-radiotherapy MRI preventing a good spectrometric analysis

          2. Patient with multifocal glioblastoma

          3. Tumor located within 2 cm of the optic chiasm

          4. Patient with leptomeningeal metastases,

          5. patients prone to epileptic seizures despite treatment with anticonvulsant

          6. Patients who received other previous treatment for glioblastoma multiforme

          7. Abnormal haematological results at inclusion with:

               -  Neutrophils &lt; 1500/mm3

               -  Blood-platelets &lt; 100000/mm3

          8. Severe or chronic renal insufficiency (creatinin clearance ≤ 30 ml/min calculated
             using Cockroft-Gault's formula

          9. Patient unable to follow procedures, visits, examinations described in the study

         10. Any usual formal indication against imaging examinations (important claustrophobia,
             pace maker ...)

         11. Pregnant women or nursing mothers can not participate in the study. Women of
             childbearing age must have a negative pregnancy test within 72 hours prior to study
             entry

         12. Men and women of childbearing age must use effective contraception at study entry and
             throughout the study

         13. Any concomitant or previous malignant disease within 5 years prior to study entry

         14. Any prior systemic chemotherapy within 5 years prior to inclusion (for malignant
             disease in medical history)

         15. Any other medical conditions making the inclusion of the patient in the study
             inappropriate in the opinion of the investigator

         16. Patient under legal guardianship
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne LAPRIE, Md</last_name>
    <phone>5 61 42 41 53</phone>
    <phone_ext>+33</phone_ext>
    <email>laprie.anne@claudiusregaud.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre VERRELLE, Pr</last_name>
      <phone>0473278142</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre.verrelle@cip.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre VERRELLE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier DURANDO, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre SUNYACH, Md</last_name>
      <phone>0478782828</phone>
      <phone_ext>+33</phone_ext>
      <email>sunyach@lyon.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre SUNYACH, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier FRAPPAZ, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP HM - Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia PADOVANI, Md</last_name>
      <phone>0491384334</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.padovani@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>laetitia PADOVANI, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine KERR, Md</last_name>
      <phone>0467613132</phone>
      <phone_ext>+33</phone_ext>
      <email>ckerr@valdorel.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Christine KERR, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel FABBRO, md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain BONAFE, pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges NOEL, Pr</last_name>
      <phone>0388252456</phone>
      <phone_ext>+33</phone_ext>
      <email>gnoel@strasbourg.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Georges NOEL, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland SCHOTT, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Izzie jacques NAMMER, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius REGAUD</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne LAPRIE, m</last_name>
      <phone>561424153</phone>
      <phone_ext>+33</phone_ext>
      <email>laprie.anne@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Anne LAPRIE, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth MOYAL, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri ROCHE, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martine DELANNES, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewa Anna COTTURA, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 16, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Intensity modulated radiation therapy (IMRT)</keyword>
  <keyword>Magnetic resonance spectroscopic imaging (MRSI)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
